Are marijuana stocks now perceived as more legitimate, without the stigma that comes with illegal drugs?
The steady drive towards cannabis legalization by U.S. states as well as many other countries also drives the marijuana stock market. Global consumers demand cannabis for both medical as well as recreational reasons. As such, companies have entered the cannabis stock market in every sector —cultivation, production, and retail. Many are creating strategic partnerships which only add to their legitimacy.
Creating legitimate marijuana stocks over the years has not been easy. Many cannabis businesses have had a tough time. In the U.S., weed is still illegal at the federal level, leaving the cannabis industry unable to secure capital or obtain insurance.
However, in some ways, the tide is changing. Many governments realize that cannabis legalization represents a way to curb black market sales. Indeed, many state and local authorities are reaping the tax benefits of “going green.” Cannabis is now more acceptable by larger groups of Americans across multiple demographics, and many Americans and American businesses feel it will just be a matter of time before cannabis is legal at the national level.
All of these strides help to propel the market in a positive direction. Research performed by ArcView Market Research and BDS Analytics shows many positive indicators not only for the North American marijuana stock market but also for the global cannabis industry.
Editor-in-Chief Tom Adams says the data shows that the market can expect very positive indicators for the rest of 2018 and beyond due to major accomplishments like Nevada’s cannabis tourism industry, as well as Californian and Canadian cannabis legalization.
These are the top five marijuana stocks improving the legitimacy of the cannabis industry:
[Read More: Innovation, Infusion, and Marijuana Stocks: Sproutly CEO Keith Dolo Has A Fresh Take On The Cannabis Industry]
Emerald Health Therapeutics Inc.
Medical cannabis companies are positively being perceived as more legitimate by the global population as a whole, as evidenced by Canadian company Emerald Health Therapeutics Inc. (OTCQX:EMHTF). This marijuana stock is a Licensed Producer under Canada's Access to Cannabis for Medical Purposes Regulations (ACMPR), who sells cannabis oils and dried cannabis products.
The company is in the process of acquiring the remaining shares of Northern Vine owned by Abattis Bioceuticals Corp. (CSE: ATT) (OTCQB: ATTBF), a Canadian licensed cannabis testing and analysis firm.
Emerald will own 100 percent of Northern, which is a licensed dealer under the Canadian Controlled Drugs and Substances Act. Licensed Dealers (LD) have privileges to conduct specific activities that Licensed Producers (LP) like Emerald do not.
For example, an LD can import and export cannabis oils and formulate cannabis products with other additives. The combination of the two companies allows this marijuana stock to venture into the ever-growing cannabis analytical testing market as well.
CLS Holdings USA Inc.
Nevada-based CLS Holdings USA Inc. (OTCQB:CLSH) just reported on the first complete year of recreational cannabis use in the state. According to the report, consumers purchased bud (50 percent), concentrates (25 percent) and infused edibles (13 percent) to account for combined medical and recreational sales.
Nevada is very popular when it comes to cannabis tourism, and CLS reports that consumers like disposable items like vape pens and pre-rolled joints.
At the end of June, this cannabis stock acquired Oasis Cannabis and is now generating $850,000 in monthly gross revenue. Oasis is a fully integrated cannabis end-to-end operation; they do it all, from growing, to extraction and processing and even operating dispensaries in the state.
With the additional capital that CLS just raised, the company has big plans to triple their production capacity by the end of 2018 to meet the increased demand in Nevada. Oasis dispensaries commonly have 400 daily visitors and served over 125,000 medical patients during this past year of recreational pot sales. About 20 percent of their total sales are for medical marijuana use, and home deliveries comprise about ten percent of total revenue.
[Read More: This Is Every State Where Weed Is Legal]
Organigram Holdings Inc.
Organigram Holdings Inc. (OTCQB:OGRMF) is another Canadian-based marijuana stock focused on high-quality and condition-specific medical cannabis strain products. They are a marijuana stock that intends to enter a three-year partnership with Hiku Brands Company Ltd., a company that supplies products via its Tokyo Smoke retail locations.
Organigram will supply cannabis oils and dried cannabis. According to a statement, Organigram said the partnership with Hiku is a strategic move for improving their branding. For example, Organigram selected strategic brands, like their award-winning Wabanaki sativa, to be a central retail feature in Tokyo Smoke stores.
GB Sciences Inc.
Another diversified marijuana stock, GB Sciences Inc. (OTCQB:GBLX) places focus on both cultivation and production methods as well as pharmaceutical research and development. GB Sciences is undertaking an effort to cultivate proprietary hemp strains for extraction of full-spectrum hemp oil rich in CBD and other cannabinoids for medical products.
The Colorado Hemp Project (CHP) was born out of the state-of-the-art cannabis genetics exemplified by GB Sciences. CHP offers best-in-breed cannabis genetics hemp research and is widely recognized as a global leader in hemp cultivation. In fact, the CHP had the first legal hemp harvest in the United States.
Leafbuyer Technologies Inc.
Leading cannabis technology firm and marijuana stock Leafbuyer Technologies Inc. (OTCQB:LBUY) just announced fourth-quarter 2018 sales that were 50 percent higher than those in the fourth-quarter of 2017.
The company attributes the increase to its strategic decision to expand its product offerings as well as to expand into new markets. Nearly a year ago, Leafbuyer began expanding into Western U.S. States like Nevada, California, Washington, Oregon, and Arizona. Director of Sales John Valle says Leafbuyer is now capitalizing on those markets.